Stepan Company

Stepan Company (SCL) Market Cap

Stepan Company has a market capitalization of $1.17B.

Financials based on reported quarter end 2025-12-31

Price: $51.42

0.63 (1.24%)

Market Cap: 1.17B

NYSE · time unavailable

CEO: Luis E. Rojo

Sector: Basic Materials

Industry: Chemicals - Specialty

IPO Date: 1992-03-17

Website: https://www.stepan.com

Stepan Company (SCL) - Company Information

Market Cap: 1.17B · Sector: Basic Materials

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products. It operates through three segments: Surfactants, Polymers, and Specialty Products. The Surfactants segment offers surfactants that are used as principal ingredients in consumer and industrial cleaning products, including detergents for washing clothes, dishes, carpets, and floors and walls, as well as shampoos and body washes; and other applications, such as fabric softeners, germicidal quaternary compounds, disinfectants, and lubricating ingredients. Its surfactants are also used in various applications, including emulsifiers for spreading agricultural products; and industrial applications comprising latex systems, plastics, and composites. The Polymers segment provides polyurethane polyols that are used in the manufacture of rigid foam for thermal insulation in the construction industry, as well as a base raw material for coatings, adhesives, sealants, and elastomers (CASE); polyester resins, including liquid and powdered products, which are used in CASE applications; and phthalic anhydride that is used in unsaturated polyester resins, alkyd resins, and plasticizers for applications in construction materials, as well as components of automotive, boating, and other consumer products. The Specialty Products segment offers flavors, emulsifiers, and solubilizers for use in food, flavoring, nutritional supplement, and pharmaceutical applications. It serves in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally. Stepan Company was founded in 1932 and is headquartered in Northbrook, Illinois.

Analyst Sentiment

83%
Strong Buy

Based on 1 ratings

Analyst 1Y Forecast: $75.00

Average target (based on 1 sources)

Consensus Price Target

Low

$75

Median

$75

High

$75

Average

$75

Potential Upside: 45.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 STEPAN (SCL) — Investment Overview

🧩 Business Model Overview

Stepan Company (NYSE: SCL) is a specialty and intermediate chemicals manufacturer, headquartered in the United States, with a global operating footprint. The company is vertically integrated in the production of surfactants, polymers, and specialty product solutions for end markets across consumer products, industrial applications, agriculture, energy, and construction. Stepan’s business model is built on innovation, close customer relationships, and technological expertise in formulation science. The company emphasizes operational efficiency and leverages a resilient global supply chain to serve multinational clients and niche markets alike. Its R&D-driven capabilities support both proprietary products and customer-specific solutions, targeting sectors with persistently high-volume needs and regulatory barriers.

💰 Revenue Streams & Monetisation Model

Stepan organizes its revenue primarily across three business segments: - Surfactants: The largest segment, supplying essential ingredients for applications in detergents, cleaning products, personal care, agriculture, oilfield, and other industrial uses. Customers span multinational household and personal care companies to industrial and institutional customers. - Polymers: This segment focuses on specialty polyols and polyester resins, critical in producing rigid foam insulation for construction, as well as coatings, adhesives, sealants, and elastomers (CASE) markets. - Specialty Products: Serving high-value-add markets like food and nutritional supplements, pharmaceuticals, and certain agricultural products, this smaller division benefits from higher margins and regulatory-driven barriers to entry. The company generates sales through long-standing supply contracts, direct sales teams, and distributor partners. Stepan’s monetisation is underpinned by scale production, product customization, technical services, and intellectual property in specialty formulations. Its global manufacturing footprint allows it to capitalize on regional market dynamics and optimize logistics costs.

🧠 Competitive Advantages & Market Positioning

Stepan’s competitive advantages stem from its combination of scale, technological capabilities, and diversified end-market exposure: - Scale and Vertical Integration: The company operates multiple manufacturing plants across North America, Europe, Latin America, and Asia, providing redundancy, flexibility, and efficient production. - Diversified Customer and End-Market Base: Stepan serves both consumer-facing and industrial customers, reducing reliance on any single market segment or economic cycle. - R&D and Formulation Expertise: A long-standing commitment to research and technical problem-solving differentiates Stepan in working with major customers on customized solutions. - Resilient Supply Relationships: Decades-long partnerships with blue-chip consumer product companies and leading industrial producers support stable demand. - Regulatory & Compliance Know-how: Navigating evolving chemical safety, environmental, and food safety regulations is a core institutional strength, often allowing Stepan to move more rapidly than less specialized competitors. The company’s scale and specialization foster high switching costs for key customers, while its innovation pipeline enables premium pricing and sustainable product differentiation.

🚀 Multi-Year Growth Drivers

Several secular and company-specific factors underpin Stepan’s multi-year growth trajectory: - Growth in Cleaning, Hygiene, and Personal Care: Long-term global urbanization and rising living standards continue to drive demand for cleaning agents and personal care products, directly supporting the surfactants segment. - Construction and Energy Efficiency: The push for energy-efficient buildings and stricter building codes accelerate adoption of polymer-based insulation materials, benefiting Stepan’s polymers business. - Sustainability and Green Chemistry: Increasing demand for bio-based, environmentally friendly surfactants and polymers aligns with Stepan’s R&D investments and sustainability initiatives. - Developing Markets Expansion: Growing consumer markets in Asia, Latin America, and Africa represent untapped potential, particularly for cleaning and building materials. - Innovation and Product Upgrading: The company’s focus on specialty formulations and higher-margin custom solutions increases wallet-share with key customers and adds recurring new revenue streams. - Strategic Acquisitions and Capacity Builds: Opportunistic acquisitions and plant expansions enable Stepan to expand both capacity and capabilities in attractive geographies and niche technologies.

⚠ Risk Factors to Monitor

Key risks to Stepan’s investment thesis include: - Raw Material Volatility: Prices for key feedstocks, such as petrochemical derivatives and natural oils, can fluctuate significantly, impacting margins if not passed through in pricing. - Regulatory Shifts: Rapid changes in chemical safety or environmental regulations could necessitate costly capital investments or limit certain product portfolios. - Customer Concentration: A significant share of revenue is tied to a few large consumer products companies, creating some customer concentration risk. - Competitive Pricing Pressures: Commodity surfactant markets are susceptible to price wars, contraction in specialty product premiums, or substituted chemistry approaches. - Foreign Exchange and Global Operations: The company’s international footprint exposes earnings to currency headwinds and local market disruptions. - Execution Risk with Expansion: Acquisitions and greenfield project build-outs carry integration and ramp-up risks.

📊 Valuation & Market View

Stepan’s valuation typically reflects the company’s reputation for stability, high return on invested capital, and resilient cash generation, balanced against the cyclical exposures of its core end-markets. Investors often assign a premium to chemical companies with strong specialty exposure, proprietary technologies, and significant barriers to entry versus commodity peers. Valuation methodologies center on a blend of price-to-earnings, EV/EBITDA multiples, and discounted cash flow analysis. Premiums may be attached on the basis of above-average EBITDA margins, free cash flow conversion, and consistent dividend growth history, while risk is discounted for cyclical sensitivity and capital expenditure requirements. Market sentiment generally aligns Stepan’s shares with broader specialty chemical sector multiples, adjusting for growth trajectory, balance sheet strength, and exposure to resilient consumer verticals.

🔍 Investment Takeaway

Stepan Company presents a compelling long-term investment story anchored in specialty chemistry’s essential role across fast-growing and defensive end-markets. The firm combines scale, innovation, and a sophisticated understanding of regulatory dynamics, positioning it as a preferred solutions provider to leading global companies. Diversification across geographies and applications supports stable earnings, while a robust balance sheet and disciplined capital allocation allow for continued investment in growth. Investors in SCL gain exposure to structural trends in global hygiene, construction efficiency, and sustainability, balanced by exposure to raw material volatility and the execution risks inherent in global chemical manufacturing. For those seeking a durable compounder in the specialty chemicals sector, Stepan represents a solid candidate with the ability to deliver attractive risk-adjusted returns over the cycle.

⚠ AI-generated — informational only. Validate using filings before investing.

Management framed 2025 as “transformational” and emphasized resilience (FY adjusted EBITDA +6% to $199M; positive free cash flow of $25.4M; leverage down to ~2.5x) while launching Project Catalyst (~$100M pretax savings, ~60% in 2026). However, the Q&A exposed near-term fragility: management guided Q1 2026 gets a ~$6M EBITDA weather-driven hit (mostly Surfactants) with only partial recovery in subsequent quarters. Surfactants remains the swing factor—Q4 Surfactants organic volume fell 3% and margin pressure persisted from oleochemical costs with a lag; recovery is explicitly expected more in 2H 2026. Catalyst savings are also not a clean offset: inflation is described as “three-plus,” and the $60M 2026 savings may be partially eaten by cost inflation. While management reiterated committed EBITDA growth for 2026, analyst pressure centered on utilization impacts, net savings vs inflation, and earnings cadence—key points where the answers were cautious and timing-skewed to later in the year.

AI IconGrowth Catalysts

  • Organic volume +2% YoY in 2025 driven by crop productivity, oilfield tier two/three, global polymers, and specialty products
  • Polymers volume +11% YoY in Q4 driven by North America and Asia rigid polyols and commodity phthalic anhydride
  • Medium chain triglycerides (specialty products) delivering double-digit volume growth
  • Pasadena alkoxylation facility ramp-up contributing to EBITDA growth and free cash flow generation in 2025

Business Development

  • Customer/channel expansion focus: tier two and tier three growth (mid single digits in 2025) with additional automation/systems to increase share in 2026
  • Strategic/technical partnerships referenced generally (no named partners/customers provided in transcript)
  • Geographic footprint flexibility: “production in the majority of the regions where we source and where we serve customers” (no named countries/customers beyond Mexico referenced as a concern by an analyst)

AI IconFinancial Highlights

  • Q4 2025 adjusted net loss of $0.5M (down $0.02/diluted share YoY); reported net income $5M (+49% YoY) largely from gain on sale of assets and nonrecurring items
  • Q4 adjusted EBITDA $33.8M vs $35.0M prior year (-3%); decline driven by Surfactants organic volumes -3% and elevated raw material costs
  • Surfactants Q4: net sales $402M vs $379M prior year; organic volume -3% YoY due to weaker demand in commodity consumer and construction/industrial end markets
  • Polymers Q4: net sales $132M vs $113M prior year; adjusted EBITDA +9% YoY on +11% volume, partially offset by lower unit margins/unfavorable mix
  • FY 2025 adjusted EBITDA +6% to $199M; FY EBITDA +11% to $208M
  • FY 2025 free cash flow positive at $25.4M (cash from operations $148M) with positive FCF also at Q4 ($25.4M vs -$0.2M prior year)
  • Leverage ratio improved from 2.8x to ~2.5x trailing twelve-month adjusted EBITDA
  • Effective tax rate headwind in Q4 (less favorable effective tax rate) and FY (higher effective tax rate); Surfactants operating income headwind; capitalized interest expense lower
  • Project Catalyst savings: ~$100M pretax over next two years; ~60% in 2026 (explicitly called out as $60M pretax in 2026) and savings skewed to second half

AI IconCapital Funding

  • Dividends: 2025 paid $8.9M; quarterly dividend declared $0.395/share payable 03/13/2026 (+2.6% YoY)
  • Net debt: $494M at Q4 end, down $32M YoY
  • 2026 CapEx guidance: $105M to $115M (analyst asked about sustaining vs discretionary; management described $110M midpoint as mainly base/infrastructure plus small growth/EHS/IT/R&D; discretionary not significant)
  • No buyback amounts or specific new debt issuance provided in transcript

AI IconStrategy & Ops

  • Project Catalyst launched: footprint optimization, operational efficiency/cost optimization, and organizational effectiveness
  • Pasadena alkoxylation facility fully commissioned in 2025; ramp expected to reach ~70% to 80% in 2026 and full utilization in 2027
  • Shutdown/exit actions: closure of Fieldsboro, NJ site due to continued lower demand in commodity surfactants for laundry detergents; decommission select assets at Millsdale and Stalybridge planned over the next few months
  • Customer impact framing: consolidation moves volume to “more modern and cost-efficient” sites to improve utilization; management stated sites are not “losing money” but are being re-allocated for better utilization/efficiency
  • Automation/system investment mentioned as part of Project Catalyst third lever and as supporting tier two/three growth; specific automation metrics not provided

AI IconMarket Outlook

  • 2026 outlook: commitment to adjusted EBITDA growth vs 2025 and positive free cash flow in 2026 despite challenges
  • Earnings cadence guidance in 2026: Q1 2026 “tough” start due to historic weather impact; management expects recovery of at least half (and hopefully more) of the Q1 EBITDA impact between Q2 and Q4
  • Weather impact quantified: ~$6M EBITDA impact in Q1 2026 (majority Surfactants; not ag)
  • Oleochemical margin timing: raw material situation significantly better in second half vs first half; margins expected to recover more in 2H 2026 than 1H
  • Demand recovery driver: expectation of at least two interest rate cuts during 2026 (management said “throughout the year, especially in the second half”) supporting construction-related demand in Polymers and some Surfactants
  • Tariffs: management expects 2026 to remain as volatile as 2025 regarding tariffs; evaluating supply chain options and potential refunds of prior tariffs

AI IconRisks & Headwinds

  • Surfactants margin pressure from oleochemical input costs with a lag: management described double-digit Surfactants EBITDA margin in Q1 2025 before oleochemical escalation; impact felt in second half 2025
  • Oleochemical lag dynamics: supply chain from Asia; inventory carry and long lead times
  • Surfactants Q4: organic volume -3% YoY due to softer demand in commodity consumer and construction/industrial solutions end markets; elevated raw material costs
  • Specialty Products Q4 modestly lower due to order timing within pharmaceutical business
  • Order timing/absorption risk in early 2026: weather caused demand loss and “absorption” issue because Q1 production wasn’t fully utilized; ~$6M EBITDA headwind in Q1 2026
  • Inflation and tariffs: management called out “unprecedented raw material inflation” and “tariff impacts” as headwinds in 2025; management guided these will continue to be volatile in 2026
  • Fixed-cost base noted explicitly: public $750M fixed costs referenced; inflation “three-plus” (approx 3% plus higher healthcare/insurance/incentives) expected to consume part of Project Catalyst savings

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the SCL Q4 2025 (FY 2025) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"SCL reported revenue of $553.9M with a net income of $5.0M and earnings per share (EPS) of $0.22. The company exhibits significant total assets of $2.36B and total liabilities of $1.11B, indicating a robust balance sheet with a total equity of $1.24B. However, the company is facing challenges in cash flow with a negative free cash flow of -$31.1M, and an operating cash flow of $59.99M amidst capital expenditures of -$91.1M. While SCL pays dividends, totaling approximately $3.56 per share recently, its market performance shows a decline of 17.09% over the past year, reflecting potential concerns among investors. Despite a stable capital structure, the company's ability to generate cash flows sustainably and effectively manage its debt remains crucial for future performance and shareholder value creation."

Revenue Growth

Neutral

Moderate revenue generation with $553.9M, showing growth potential but subject to market conditions.

Profitability

Caution

Low net income of $5.0M indicates pressure on margins, resulting in a limited profit for shareholders.

Cash Flow Quality

Neutral

Negative free cash flow points to cash generation issues despite positive operating cash flow.

Leverage & Balance Sheet

Positive

Healthy equity position with total assets of $2.36B against $1.11B liabilities, manageable debt levels.

Shareholder Returns

Neutral

Declining stock price and negative return suggest that the shareholder returns are currently not favorable.

Analyst Sentiment & Valuation

Fair

Market perception shows skepticism with a target price of $75 but recent performance dissuades optimism.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
📁

SEC Filings (SCL)

© 2026 Stock Market Info — Stepan Company (SCL) Financial Profile